Pembrolizumab-PET Imaging

Summary

This is a two center, single arm, investigator sponsored trial (IST) with the PET tracer 89Zr-pembrolizumab to evaluate in vivo whole body distribution of 89Zr-Pembrolizumab in a registered indication: locally advanced metastatic melanoma or non-small cell lung cancer before Pembrolizumab treatment.

Timeline

Start

2016-10-24

Primary completion

2019-03

Completion

2020-09

Publications

• Qi C, Guo R, Chen Y, Li C, Liu C, Zhang M, Zhang C, Zhang X, Hou X, Chen B, Jia B, Yang Z, Shen L, Zhu H. 68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients. J Nucl Med. 2024 Jun 3;65(6):856-863. doi: 10.2967/jnumed.123.267110.
• Li W, Wang Y, Rubins D, Bennacef I, Holahan M, Haley H, Purcell M, Gantert L, Hseih S, Judo M, Seghezzi W, Zhang S, van der Veen EL, Lub-de Hooge MN, de Vries EGE, Evelhoch JL, Klimas M, Hostetler ED. PET/CT Imaging of 89Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys. Mol Imaging Biol. 2021 Apr;23(2):250-259. doi: 10.1007/s11307-020-01558-w. Epub 2020 Oct 26.

Drugs

Indications